Article Details
Retrieved on: 2023-12-08 18:14:54
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Editor's note: Dr Jhaveri cited receiving funding from AstraZeneca, BluePrint Medicines, Genentech/Roche, Gilead, Lilly Pharmaceuticals/Loxo ...
Article found on: www.onclive.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here